In a world of constant change, one thing remains steady: Americans love for chocolate. Today we focus on the ultimate “forever stock.” Backed up by more than a century of brand power, this business will remain as relevant for our children and grandchildren as it was for our parents and grandparents.
Dear Biotech Frontiers Subscribers: We have two timely pieces of news to digest. 1. This past Friday, February 16, the Food and Drug Administration (“FDA”) granted Iovance Biotherapeutics’ (Nasdaq: IOVA) lifileucel therapy accelerated approval for advanced melanoma, making it the first and only tumor-infiltrating lymphocyte (“TIL”) treatment available for cancer. Lifileucel’s approval is an important
As a sector, biotech stocks perform differently than tech stocks, “forever stocks,” and certainly the blue chips… We asked biotech veteran Erez Kalir to explain, in his own words, how he finds the right stocks for our new advisory Biotech Frontiers.
While this company may not be familiar to many people, its iconic brands certainly are. But because of corporate missteps, the owner of these gear and apparel makers has hit hard times — which we now see as an opportunity
In the midst of the market tumult and a broken merger, this company’s bonds felt a sharp decline in price. For analyst Martin Fridson this distress has created a very appealing new opportunity.
The “Fixer,” a leading global provider of litigation financing, funds lawsuits and takes a cut of the payout when it wins. This highly profitable and capital efficient business model can turn small investments into supersized returns.
In this issue of Biotech Frontiers, we’ll lay out why one doctor’s five decades of pioneering work in oncology has not been simply an academic exercise… but instead stands to transform the lives of many cancer patients and reward this company’s shareholders who have funded its development.
Action to Take: Buy Shares of Mercury Systems (MRCY) On February 6, after the market closed, Mercury Systems (Nasdaq: MRCY) reported earnings for its second quarter 2024 fiscal year – for the period ending December 2023. As is often the case with companies in a turnaround mode, the results were not good. In fact, company
Dear Porter & Co. Biotech Frontiers Subscribers: One of the defining aspects of biotech is that it’s a catalyst-driven investment domain. This means that the fate of biotech investments often depends on specific, concrete events – such as clinical-trial-data releases or regulatory decisions. These decisions can drive biotech stocks much higher… or much lower. This
